Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Market Intelligence United States

Cigna Adopts $0 Stelara Biosimilar Program More Rapidly Than For Humira

Move To Make Ustekinumab Available Via Accredo Follows Similar Adalimumab Initiative

  • Analysis

Executive Summary

Cigna’s Evernorth has announced a program that will see the PBM offer in the US an unidentified ustekinumab biosimilar at $0 out of pocket for its Accredo patients from early next year. The move follows a similar initiative for adalimumab – but is set to come much sooner after Stelara’s biosimilar market formation than it did for Humira.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Tags:
Biosimilars Market Intelligence United States
Latest Headlines

US Interchangeability ‘Irrelevant’ And ‘Makes No Sense’ Says Sandoz

Future Of GLP-1s: Iconovo Starts Development Of Intranasal Semaglutide

Final Chance To Have Your Say: Take Our Reader Survey This Week

Adalvo Puts GLP-2 Agonist Teduglutide In The Crosshairs With ‘Day-1’ Filing

See All
UsernamePublicRestriction

Register

GB153771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By